What This FDA News Could Mean for AbbVie's Stock
Earlier this month, AbbVie (NYSE: ABBV) completed its application to the U.S. Food and Drug Administration (FDA) for Rinvoq to treat adults with a back arthritis (known as non-radiographic axial spondyloarthritis) who previously tried nonsteroidal anti-inflammatory drugs (NSAIDs) but did not benefit. If eventually approved by the FDA, this would be the fourth approved indication in the U.S. for Rinvoq. Let's take a look at Rinvoq's efficacy in treating patients with this form of back arthritis and the sales potential of the indication for pharma stock AbbVie.